Metastatic Leiomyosarcoma Biomarker Protocol

Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · Dec 7, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on studying a type of cancer called metastatic leiomyosarcoma (LMS), which is a serious condition where the cancer has spread from its original site to other parts of the body. The researchers want to find out if a specific type of DNA found in the blood, called circulating tumor DNA (ctDNA), can help predict how well patients respond to chemotherapy. By analyzing blood samples and tumor tissues from patients undergoing treatment, the study aims to identify early signs that could indicate whether the chemotherapy is working, which could significantly help in planning future treatments.

To be eligible for this trial, patients must have advanced leiomyosarcoma that cannot be surgically removed and must be starting their first round of chemotherapy using specific drugs. There are no age restrictions, but participants must also have certain tumor characteristics. Those who join the study can expect to provide blood samples, tumor tissue, and complete a questionnaire about their views on genetics and genetic testing. This research is actively recruiting participants, and it's an important step toward improving treatment strategies for this challenging cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with unresectable or metastatic leiomyosarcoma (LMS). There is no age requirement
• • Receiving first-line chemotherapy with doxorubicin or gemcitabine/docetaxel
• • Target lesions per RECIST 1.1
• • Optional archival tumor tissue including 1 H\&E-stained slide and unstained tumor tissue \[either tissue block containing tumor, or minimum of 4 unstained slides (preferably 8 unstained slides)-fresh frozen sample may also be used in lieu of FFPE sample\] available for study research

Trial Officials